Company / EPS (Diluted)
Protara Therapeutics, Inc. EPS (Diluted) History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.16
FY2016
5-year range
-$61.16 / -$3.16
FY2014-FY2016
Trend
+94.7%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-61.16 to $-3.16 over the past 2 years.
Based on SEC 10-K filings.
-3.16 in FY2016.
Improved from $-61.16 to $-3.16 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, eps (diluted) increased 94.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.74 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2016 | -$3.16 | +94.7% |
| FY2015 | -$59.66 | +2.5% |
| FY2014 | -$61.16 | - |
As of FY2016 · SEC 10-K · Updated Jun 28, 2026